Dolasetron Mesylate Injection Shortage
Last Updated: July 14, 2017
Status: Resolved
Products Affected - Description
-
- Anzemet intravenous injection, Validus Pharmaceuticals, 100 mg, 5 mL single dose vial, 1 count, NDC 00088-1206-32
- Anzemet intravenous injection, Validus Pharmaceuticals, 12.5 mg, 0.625 mL single dose vial, 6 count, NDC 00088-1208-06
- Anzemet intravenous injection, Validus Pharmaceuticals, 500 mg, 25 mL multiple dose vial, 1 count, NDC 00088-1209-26
Reason for the Shortage
-
- Validus Pharmaceuticals acquired Anzemet injection from Sanofi US in December 2015.
- Validus Pharmaceuticals has temporarily discontinued all Anzemet injection presentations and cannot estimate a resupply date.
Estimated Resupply Dates
-
- Validus Pharmaceuticals has temporarily discontinued all Anzemet injection presentations and the company cannot estimate a resupply date.
Updated
Updated July 14, 2017 by Leslie Jensen, PharmD, Drug Information Specialist. Created February 29, 2016 by Leslie Jensen, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.